NA:GLPG Galapagos NV

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. It also has a research and development agreement with Pharnext SA to develop a pipeline of synergistic drug combinations for various indications; and a research collaboration agreement with ProQR Therapeutics N.V. to discover Axiomer Editing Oligonucleotides against fibrosis targets. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.This company has ADRs that trade in the U.S. as the symbol GLPG.

43.31 EUR
As of 12/06/2021


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Belgium
Country of incorporation:  Belgium
IPO date:  05/06/2005
Stock exchange:    Nyse Euronext - Euronext
Exchange country:   The Netherlands
Market cap:   2,779,787,732 EUR
Current dividend yield:   0.00%
CUSIP:    B44170106
ISIN:        BE0003818359
Sedol:      B07Q2V5

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy